The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Active-comparator design and new-user design in observational studies
Open accessAbstract
Over the past decade, an increasing number of observational studies have examined the effectiveness or safety of treatments for rheumatoid arthritis. Unlike randomized controlled trials (RCTs), however, observational studies of drug effects have methodological limitations such as confounding by indication. Active-comparator designs and new-user designs can help mitigate such biases in observational studies and improve the validity of their findings by making them more closely approximate RCTs. In an active-comparator study, the drug of interest is compared with another agent commonly used for the same indication, rather than with no treatment (a 'non-user' group). This principle helps to ensure that treatment groups have similar treatment indications, attenuating both measured and unmeasured differences in patient characteristics. The new-user study includes a cohort of patients from the time of treatment initiation, enabling assessment of patients' pretreatment characteristics and capture of all events occurring during follow-up. These two principles should be considered when designing or reviewing observational studies of drug effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Overadjustment bias and unnecessary adjustment in epidemiologic studies.
Schisterman, E. F., Cole, S. R., & Platt, R. W. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a819a1 · Cited by 2,096
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Levesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,182
Dealing with limited overlap in estimation of average treatment effects
Crump, R. K., Hotz, V. J., Imbens, G. W., & Mitnik, O. A. (2009) · Biometrika · doi:10.1093/biomet/asn055 · Cited by 1,007
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
The Identification of Frailty: A Systematic Literature Review
Sternberg, S. A., Schwartz, A. W., Karunananthan, S., Bergman, H., & Mark Clarfield, A. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03597.x · Cited by 703
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Galloway, J. B., Hyrich, K. L., Mercer, L. K., Dixon, W. G., Fu, B., Ustianowski, A. P., Watson, K. D., Lunt, M., BSRBR Control Centre Consortium, Symmons, D. P. M., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/keq242 · Cited by 676
Immortal time bias in observational studies of drug effects
Suissa, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1357 · Cited by 584
Diagnosing and responding to violations in the positivity assumption
Petersen, M. L., Porter, K. E., Gruber, S., Wang, Y., & van der Laan, M. J. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280210386207 · Cited by 548
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
Geborek, P., Bladström, A., Turesson, C., Gulfe, A., Petersson, I. F., Saxne, T., Olsson, H., & Jacobsson, L. T. H. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030528 · Cited by 427
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398
Strangfeld, A., Eveslage, M., Schneider, M., Bergerhausen, H. J., Klopsch, T., Zink, A., & Listing, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151043 · Cited by 367
Grijalva, C. G., Chen, L., Delzell, E., Baddley, J. W., Beukelman, T., Winthrop, K. L., Griffin, M. R., Herrinton, L. J., Liu, L., Ouellet-Hellstrom, R., et al. (2011) · JAMA · doi:10.1001/jama.2011.1692 · Cited by 350
Self-citationWolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22579 · Cited by 348
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22808 · Cited by 307
Gottenberg, J. ‐., Ravaud, P., Bardin, T., Cacoub, P., Cantagrel, A., Combe, B., Dougados, M., Flipo, R. M., Godeau, B., Guillevin, L., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27555 · Cited by 305
den Broeder, A. A., Creemers, M. C. W., Fransen, J., et al. (2007) · PubMed · Cited by 280
Greenberg, J. D., Reed, G., Kremer, J. M., Tindall, E., Kavanaugh, A., Zheng, C., Bishai, W., & Hochberg, M. C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.089276 · Cited by 275
Giles, J. T., Bartlett, S. J., Gelber, A. C., Nanda, S., Fontaine, K. R., Ruffing, V., & Bathon, J. M. (2006) · Arthritis Care & Research · doi:10.1002/art.21841 · Cited by 267
Strangfeld, A., Hierse, F., Rau, R., Burmester, G.-R., Krummel-Lorenz, B., Demary, W., Listing, J., & Zink, A. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2904 · Cited by 264
British Society for Rheumatology Biologics Register
Silman, A. J., Symmons, D. P. M., Scott, D. G. I., & Griffiths, I. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.suppl_2.ii28 · Cited by 248
The incident user design in comparative effectiveness research
Johnson, E. S., Bartman, B. A., Briesacher, B. A., Fleming, N. S., Gerhard, T., Kornegay, C. J., Nourjah, P., Sauer, B., Schumock, G. T., Sedrakyan, A., et al. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3334 · Cited by 241
Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
Setoguchi, S., Solomon, D. H., Weinblatt, M. E., Katz, J. N., Avorn, J., Glynn, R. J., Cook, E. F., Carney, G., & Schneeweiss, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22056 · Cited by 240
Self-citationRaaschou, P., Simard, J. F., Holmqvist, M., Askling, J., & for the ARTIS Study Group (2013) · BMJ · doi:10.1136/bmj.f1939 · Cited by 213
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Takei, S., Tanaka, Y., Sano, Y., Yaguramaki, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130466 · Cited by 208
Galloway, J. B., Hyrich, K. L., Mercer, L. K., Dixon, W. G., Ustianowski, A. P., Helbert, M., Watson, K. D., Lunt, M., & Symmons, D. P. M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.152769 · Cited by 205
Dixon, W. G., Watson, K. D., Lunt, M., Mercer, L. K., British Society For Rheumatology Biologics Register Control Centre Consortium, Hyrich, K. L., Symmons, D. P. M., & British Society for Rheumatology Biologics Register (2010) · Arthritis Care & Research · doi:10.1002/acr.20129 · Cited by 200
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Takei, S., Tanaka, Y., Ito, K., & Yamanaka, H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151092 · Cited by 194
Schneeweiss, S., Gagne, J. J., Glynn, R. J., Ruhl, M., & Rassen, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.235 · Cited by 192
Paradoxical Relations of Drug Treatment with Mortality in Older Persons
Glynn, R. J., Knight, E. L., Levin, R., & Avorn, J. (2001) · Epidemiology · doi:10.1097/00001648-200111000-00017 · Cited by 181
Galloway, J. B., Mercer, L. K., Moseley, A., Dixon, W. G., Ustianowski, A. P., Helbert, M., Watson, K. D., Lunt, M., Hyrich, K. L., & Symmons, D. P. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201108 · Cited by 174
Atzeni, F., Sarzi-Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E. G., Frati, E., Foschi, V., Gasparini, S., Giardina, A., et al. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.06.008 · Cited by 169
Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., & Dougados, M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel236 · Cited by 168
Serious infections during anti-TNFα treatment in rheumatoid arthritis patients
Favalli, E. G., Desiati, F., Atzeni, F., Sarzi‐Puttini, P., Caporali, R. F., Bobbio‐Pallavicini, F., Gorla, R., Filippini, M., & Marchesoni, A. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.11.002 · Cited by 164
Psaty, B. M., & Siscovick, D. S. (2010) · JAMA · doi:10.1001/jama.2010.1205 · Cited by 159
Dartel, S. A. A. R.-V., Fransen, J., Kievit, W., Flendrie, M., den Broeder, A. A., VISSER, H. K. A., Hartkamp, A., van de Laar, M. A. F. J., & van Riel, P. L. C. M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201338 · Cited by 156
Textbook of Pharmacoepidemiology
Strom, B. L., Kimmel, S. E., & Hennessy, S. (2013) · Wiley eBooks · doi:10.1002/9781118344828 · Cited by 153
Risk of infections in rheumatoid arthritis patients treated with tocilizumab.
Lang, V. R., Englbrecht, M., Rech, J., Nüßlein, H., Manger, K., Schuch, F., Tony, H., Fleck, M., Manger, B., Schett, G., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/ker223 · Cited by 127
Solomon, D. H., Kremer, J. M., Fisher, M. C., Curtis, J. R., Furer, V., Harrold, L. R., Hochberg, M. C., Reed, G. W., Tsao, P., & Greenberg, J. D. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.08.003 · Cited by 122
Self-citationCurtis, J. R., Xie, F., Chen, L., Baddley, J. W., Beukelman, T., Saag, K. G., Spettell, C. M., Mcmahan, R. M., Fernandes, J., Winthrop, K. L., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146365 · Cited by 119
Curtis, J. R., Yang, S., Patkar, N. M., Chen, L., Singh, J. A., Cannon, G. W., Mikuls, T. R., Delzell, E., Saag, K. G., Safford, M. M., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22281 · Cited by 109
Mortality Reduction with Influenza Vaccine in Patients with Pneumonia Outside “Flu” Season
Eurich, D. T., Marrie, T. J., Johnstone, J., & Majumdar, S. R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-282oc · Cited by 108
Selection bias in rheumatic disease research
Choi, H. K., Nguyen, U., Niu, J., Danaei, G., & Zhang, Y. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.36 · Cited by 104
Yun, H., Xie, F., Delzell, E., Chen, L., Levitan, E. B., Lewis, J. D., Saag, K. G., Beukelman, T., Winthrop, K. L., Baddley, J. W., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204011 · Cited by 101
García‐Vidal, C., Fernández, S. R., Teijón, S., Esteve, M., Rodríguez‐Carballeira, M., Lacasa, J., Salvador, G., & Garau, J. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0628-x · Cited by 96
Curtis, J. R., Xi, J., Patkar, N. M., Xie, A., Saag, K. G., & Martin, C. K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23050 · Cited by 93
Lane, M., McDonald, J. R., Zeringue, A., Caplan, L., Curtis, J. R., Ranganathan, P., & Eisen, S. A. (2011) · Medicine · doi:10.1097/md.0b013e318211106a · Cited by 86
Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry
Bobbio‐Pallavicini, F., Caporali, R. F., Sarzi‐Puttini, P., Atzeni, F., Bazzani, C., Gorla, R., Marchesoni, A., Favalli, E. G., & Montecucco, C. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.07.006 · Cited by 81
Peña-Sagredo, J. L., Hernández, M. V., Fernández-Llanio, N., Giménez-Ubeda, E., Muñoz‐Fernández, S., Ortiz, A. J. S., González-Gay, M. Á., & Fariñas, M. C. (2008) · PubMed · Cited by 69
Morgan, C. L., Emery, P., Porter, D. R., Reynolds, A., Young, A., Boyd, H., Poole, C., & Currie, C. J. (2013) · Lara D. Veeken · doi:10.1093/rheumatology/ket333 · Cited by 64
Curtis, J. R., Xie, F., Chen, L., Muntner, P., Grijalva, C. G., Spettell, C. M., Fernandes, J. F., Mcmahan, R. M., Baddley, J. W., Saag, K. G., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21805 · Cited by 62
Mycobacterial Infections in Patients Treated with Tumor Necrosis Factor Antagonists in South Korea
Lee, S. K., Kim, S. Y., Kim, E. Y., Jung, J. Y., Park, M. S., Kim, Y. S., Kim, S. I., Chang, J., & Kang, Y. A. (2013) · Lung · doi:10.1007/s00408-013-9481-5 · Cited by 60
Self-citationObservational studies of drug safety
Walker, A. M., & Stampfer, M. J. (1996) · The Lancet · doi:10.1016/s0140-6736(05)64664-8 · Cited by 45
Johnston, S. S., Turpcu, A., Shi, N., Fowler, R., Chu, B. C., & Alexander, K. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.12.024 · Cited by 41
Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort
Slimani, S., Lukas, C., Combe, B. G., & Morel, J. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.11.012 · Cited by 40
Bello, S. L., Serafino, L., Bonali, C., et al. (2012) · Reumatismo · doi:10.4081/reumatismo.2012.299 · Cited by 28
Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo, J. L., Fariñas, M. C., Pérez-Zafrilla, B., Cruz-Valenciano, A., Casal, M. C., Joven-Ibáñez, B., Riera, E., Ruíz, F. J. M., Chalmeta, I., Hernández, M. V., et al. (2009) · PubMed · Cited by 26
Dewedar, A. M., Shalaby, M., Al‐Homaid, S., Mahfouz, A. A., Shams, O. A., & Fathy, A. (2012) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2012.01715.x · Cited by 24
Neven, N., Vis, M., Voskuyl, A. E., Wolbink, G., Nurmohamed, M. T., Dijkmans, B. A. C., & Lems, W. F. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.028597 · Cited by 24
Hoffman, V., Norman, H. S., Alexander, K. A., Napalkov, P., & Enger, C. L. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.05.004 · Cited by 18
Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab
Chiang, Y.-C., Kuo, L., Yen, Y.-H., Tang, C., & Chen, H. (2014) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2014.06.008 · Cited by 16
Castillo, W. C., Delaney, J. A., & Stürmer, T. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3602 · Cited by 4
Cited by
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7193 · Cited by 729
Effect of IBD medications on COVID-19 outcomes: results from an international registry
Ungaro, R. C., Brenner, E. J., Gearry, R. B., Kaplan, G. G., Kissous-Hunt, M., Lewis, J. D., Ng, S. C., Rahier, J.-F., Reinisch, W., Steinwurz, F., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322539 · Cited by 277
Pawar, A., Desai, R. J., Solomon, D. H., Santiago Ortiz, A. J., Gale, S., Bao, M., Sarsour, K., Schneeweiss, S., & Kim, S. C. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214367 · Cited by 181
Self-citationMansi, I. A., Chansard, M., Lingvay, I., Zhang, S., Halm, E. A., & Alvarez, C. A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5714 · Cited by 144
Xu, J., Mao, C., Hou, Y., Luo, Y., Binder, J. L., Zhou, Y., Bekris, L. M., Shin, J., Hu, M., Wang, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111717 · Cited by 115
Metadata
- Authors
- Yoshida, K., Solomon, D. H., & Kim, S. C.
- Venue
- Nature Reviews Rheumatology
- Published
- 2015-03-24
- Volume
- 11
- Issue
- 7
- Pages
- 437-441
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W1964098393
- Cited by
- 406
- References
- 66
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.